Figures computed from official regulatory filings — .
Analysttarget 328.33 USD (-14%) · consensus 3/5 · 1 buy · 1 hold · 1 sell
Ownershipinsiders 16.41% · institutions 91.57% · short 6.3% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for BIO-RAD LABORATORIES, INC. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
7 buys324 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| SCHWARTZ NORMAN D | Exercise | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Lakkaraju Roop Kalyantrack record | Other | $301.9K | SEC |
| Lakkaraju Roop Kalyantrack record | Other | $215.8K | SEC |
| Lakkaraju Roop Kalyantrack record | Exercise | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| ENLOE COURTNEY C | Other | $117.8K | SEC |
| Mehta Rajat | Exercise | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Mehta Rajat | Other | $194.6K | SEC |
| Mehta Rajat | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| BARRY JAMES | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Lakkaraju Roop Kalyantrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| ENLOE COURTNEY C | Exercise | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Mehta Rajat | Other | $90K | SEC |
| SCHWARTZ NORMAN D | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| DiVincenzo Jonathan | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| DiVincenzo Jonathan | Exercise | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| EVRAN SEDAT | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| SCHWARTZ NORMAN D | Other | $715.8K | SEC |
| EVRAN SEDAT | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| ENGELHARDT EVA ANETTE | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| ENLOE COURTNEY C | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| SCHWARTZ NORMAN D | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| ENGELHARDT EVA ANETTE | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| EVRAN SEDAT | Exercise | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Allison Schwartz | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| SCHWARTZ NORMAN D | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |